Loading clinical trials...

Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT. | Clinical Trials | Clareo Health

COMPLETED

Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.

Dynamic Optical Coherence Tomography (D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.

NCT03767400•Allergan

View on ClinicalTrials.gov

Summary

This single-center clinical study is being conducted over the course of 2 weeks to conduct an exploratory pilot study as a preliminary evaluation of D-OCT's ability to measure skin changes from aging. Assess structural differences between young and aged skin on the face. To identify the structural characteristics of atrophic acne scars relative to normal skin on the face. To explore characteristics of cellulite relative to normal skin on the thigh in young and aged skin.

Eligibility

Age

18 - 75 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Female Caucasian subjects with Fitzpatrick skin types I-III that meet one of the criteria listed below:
•1. Ages 18-30 years old without acne scars on the face with or without visible cellulite on posterior thigh, or
•2. Ages 55-75 years old without acne scars on the face with or without visible cellulite on posterior thigh, or
•3. Ages 18-75 years old with atrophic acne scars
•Subject has completed an appropriately administered informed consent process which includes signing the IRB approved consent form.
•Good general health and free of any disease state or physical condition (e.g. psoriasis, rosacea, scars, tattoos etc.) which, in the investigator's opinion, might impair evaluations of the test sites or expose the subject to an unacceptable risk by study participation.
•Willingness to remove all makeup on the day of the visit. Makeup may be applied after the study visit has been completed.
•Willingness to cleanse their face and remove all face makeup at each scheduled clinic visit. No other topical products should be applied to the face until the study visit has been completed.
•i. For cellulite subgroup, willingness to have thigh cleansed at each scheduled clinic visit.
•Willingness to have investigator exams, skin instrumentation measurements, and digital photos performed on the face and/or thigh (for cellulite subgroup).
+1 more criteria

Exclusion Criteria

•Has any condition that, in the opinion of the investigator, would make it unsafe for the subject to participate in the study or interfere with their clinical assessments (including conditions that require the concurrent use of anticoagulants, bleeding coagulopathies, photosensitivity diseases).
•Individuals with active symptoms of allergy, cold sore or warts, active psoriasis or eczema, rosacea, sunburn, open wounds, neurotic excoriations, tattoos, or other skin conditions in the test areas that would interfere with the assessments of this study.
•Individuals who are pregnant.
•Uncontrolled disease such as diabetes, hypertension, hyper or hypo-thyroidism, active hepatitis, immune deficiency, or autoimmune.
•Individuals who have a pre-existing or dormant dermatologic condition (e.g. history of severe psoriasis, atopic dermatitis, rosacea, skin cancer, etc.)
•Individuals who have routinely used any of the following topical products, prescription products, or had any of the listed treatments/procedures within the listed time frame prior to study entry or will use during study:
•1. Any product that the investigator deems that could affect the study objectives. These include products that address skin imperfections. This does not include a basic cleanser, moisturizer and sunscreen.(time frame 2 weeks)
•2. Chemical peel, microdermabrasion, dermaplaning, or microneedling (time frame 3 months)
•3. Retin-A®, Retin-A Micro®, Renova®, Avita®, Tazorac®, Avage® or Differin® or other similar prescription drugs (time frame 3 months)
•4. Cosmetic injections (filler and/or toxins, i.e. Juvederm, Radiesse, Botox, etc.), non-ablative laser or fractional laser resurfacing (time frame 12 months)
+4 more criteria

Locations (1)

Skinmedica Clinical Research and Innovation Center

Irvine, California, United States

Key Dates

Start Date

December 7, 2018

Primary Completion Date

May 31, 2019

Completion Date

July 30, 2019

Last Updated

October 31, 2019

Enrollment

ACTUAL participants

Conditions

Skin Care

Interventions

Skin Imaging

DEVICE

Facial Cleanser

OTHER

Evaluation of the EF192B Protection Versus No Treatment

NCT06752460

Skin LesionsSkin Care

View study

UNKNOWNNA

The Effect of Almond and Extra Virgin Olive Oils on Maintaining Skin Integrity in Neonates

NCT06286813

Skin Care

View study

COMPLETEDNA

A Study to Assess the Local Cutaneous and Ocular Tolerance of Three Developmental Facial Skin-care Formulations.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 31, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.

Inclusion Criteria

Exclusion Criteria

Evaluation of the EF192B Protection Versus No Treatment

The Effect of Almond and Extra Virgin Olive Oils on Maintaining Skin Integrity in Neonates

A Study to Assess the Local Cutaneous and Ocular Tolerance of Three Developmental Facial Skin-care Formulations.

The Effect of Skin Care Applied With Two Different Oils on Skin Integrity and Growth Parameters in Premature Babies

To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Facial Products

A Study to Evaluate of Cosmetic Benefit of a Moisturising Cream in People With Blemish Prone Skin